Partially matched transplants with allogeneic CD34+ blood cells

Tsutomu Watanabe, Shin Mineishi, Yoshifumi Kawano, Yoichi Takaue

Research output: Contribution to journalReview article

Abstract

Allogeneic CD34+ selected cell transplantation from a partially matched donor is feasible for the treatment of hematopoietic malignancies. Severe graft-versus-host disease (GvHD) can be prevented by this approach, and a lengthy search for an unrelated donor can be avoided. However, long-term engraftment is still a challenge, and may require intensified conditioning regimens with severe toxicities to sustain engraftment. Furthermore, unacceptable effects such as relapse and life-threatening viral infections might be more frequent after such transplants compared with non-T-cell-depleted transplants from an HLA-identical donor. Strict indications should be considered for this treatment based on a risk/benefit assessment for very high-risk patients. The early application of periodic donor leukocyte infusion (DLI) may be useful for preventing both late graft rejection and serious viral infections.

Original languageEnglish (US)
Pages (from-to)487-496
Number of pages10
JournalLeukemia and Lymphoma
Volume37
Issue number5-6
DOIs
StatePublished - Jan 1 2000

Fingerprint

Blood Cells
Tissue Donors
Virus Diseases
Transplants
Unrelated Donors
Cell Transplantation
Graft Rejection
Graft vs Host Disease
Hematologic Neoplasms
Leukocytes
Recurrence
Therapeutics

All Science Journal Classification (ASJC) codes

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Watanabe, Tsutomu ; Mineishi, Shin ; Kawano, Yoshifumi ; Takaue, Yoichi. / Partially matched transplants with allogeneic CD34+ blood cells. In: Leukemia and Lymphoma. 2000 ; Vol. 37, No. 5-6. pp. 487-496.
@article{15508b9b523a426f8507a44376b99dee,
title = "Partially matched transplants with allogeneic CD34+ blood cells",
abstract = "Allogeneic CD34+ selected cell transplantation from a partially matched donor is feasible for the treatment of hematopoietic malignancies. Severe graft-versus-host disease (GvHD) can be prevented by this approach, and a lengthy search for an unrelated donor can be avoided. However, long-term engraftment is still a challenge, and may require intensified conditioning regimens with severe toxicities to sustain engraftment. Furthermore, unacceptable effects such as relapse and life-threatening viral infections might be more frequent after such transplants compared with non-T-cell-depleted transplants from an HLA-identical donor. Strict indications should be considered for this treatment based on a risk/benefit assessment for very high-risk patients. The early application of periodic donor leukocyte infusion (DLI) may be useful for preventing both late graft rejection and serious viral infections.",
author = "Tsutomu Watanabe and Shin Mineishi and Yoshifumi Kawano and Yoichi Takaue",
year = "2000",
month = "1",
day = "1",
doi = "10.3109/10428190009058501",
language = "English (US)",
volume = "37",
pages = "487--496",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",
number = "5-6",

}

Partially matched transplants with allogeneic CD34+ blood cells. / Watanabe, Tsutomu; Mineishi, Shin; Kawano, Yoshifumi; Takaue, Yoichi.

In: Leukemia and Lymphoma, Vol. 37, No. 5-6, 01.01.2000, p. 487-496.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Partially matched transplants with allogeneic CD34+ blood cells

AU - Watanabe, Tsutomu

AU - Mineishi, Shin

AU - Kawano, Yoshifumi

AU - Takaue, Yoichi

PY - 2000/1/1

Y1 - 2000/1/1

N2 - Allogeneic CD34+ selected cell transplantation from a partially matched donor is feasible for the treatment of hematopoietic malignancies. Severe graft-versus-host disease (GvHD) can be prevented by this approach, and a lengthy search for an unrelated donor can be avoided. However, long-term engraftment is still a challenge, and may require intensified conditioning regimens with severe toxicities to sustain engraftment. Furthermore, unacceptable effects such as relapse and life-threatening viral infections might be more frequent after such transplants compared with non-T-cell-depleted transplants from an HLA-identical donor. Strict indications should be considered for this treatment based on a risk/benefit assessment for very high-risk patients. The early application of periodic donor leukocyte infusion (DLI) may be useful for preventing both late graft rejection and serious viral infections.

AB - Allogeneic CD34+ selected cell transplantation from a partially matched donor is feasible for the treatment of hematopoietic malignancies. Severe graft-versus-host disease (GvHD) can be prevented by this approach, and a lengthy search for an unrelated donor can be avoided. However, long-term engraftment is still a challenge, and may require intensified conditioning regimens with severe toxicities to sustain engraftment. Furthermore, unacceptable effects such as relapse and life-threatening viral infections might be more frequent after such transplants compared with non-T-cell-depleted transplants from an HLA-identical donor. Strict indications should be considered for this treatment based on a risk/benefit assessment for very high-risk patients. The early application of periodic donor leukocyte infusion (DLI) may be useful for preventing both late graft rejection and serious viral infections.

UR - http://www.scopus.com/inward/record.url?scp=0034100103&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034100103&partnerID=8YFLogxK

U2 - 10.3109/10428190009058501

DO - 10.3109/10428190009058501

M3 - Review article

C2 - 11042509

AN - SCOPUS:0034100103

VL - 37

SP - 487

EP - 496

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 5-6

ER -